GlaxoSmithKline plc (LON:GSK) has been given an average recommendation of “Hold” by the seventeen research firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is GBX 1,557.47 ($20.35).
A number of analysts have recently commented on GSK shares. The Goldman Sachs Group set a GBX 1,870 ($24.43) price target on GlaxoSmithKline in a research note on Wednesday, July 7th. Shore Capital reissued a “hold” rating on shares of GlaxoSmithKline in a report on Tuesday, June 22nd. Barclays set a GBX 1,300 ($16.98) price target on shares of GlaxoSmithKline in a research report on Monday. Deutsche Bank Aktiengesellschaft upgraded shares of GlaxoSmithKline to a “hold” rating and lifted their price target for the stock from GBX 1,300 ($16.98) to GBX 1,350 ($17.64) in a report on Thursday, June 24th. Finally, UBS Group set a GBX 1,500 ($19.60) price objective on GlaxoSmithKline in a report on Monday.
In related news, insider Urs Rohner purchased 629 shares of the firm’s stock in a transaction on Wednesday, April 28th. The stock was purchased at an average cost of GBX 1,340 ($17.51) per share, with a total value of £8,428.60 ($11,012.02). Insiders bought a total of 648 shares of company stock valued at $869,140 in the last quarter.
The business also recently disclosed a dividend, which was paid on Thursday, July 8th. Stockholders of record on Thursday, May 20th were given a dividend of GBX 19 ($0.25) per share. This represents a dividend yield of 1.42%. The ex-dividend date of this dividend was Thursday, May 20th. GlaxoSmithKline’s dividend payout ratio (DPR) is 0.77%.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Read More: 52-week highs
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.